Membrane type 1 matrix metalloproteinase detection in tumors, using the iodinated endogenous [123I]-tissue inhibitor 2 of metalloproteinases as imaging agent.
Van Steenkiste, Magali; Oltenfreiter, Ruth; Frankenne, Franciset al.
2010 • In Cancer Biotherapy and Radiopharmaceuticals, 25 (5), p. 511-20
[en] Matrix metalloproteinases (MMPs) are principal participants in tumor development. In addition to serve as a useful biochemical marker, MMP expression may also provide a target for the diagnostic in vivo imaging of tumors, using a radiolabeled inhibitor. This study investigates the use of membrane type 1 (MT1)-MMP as target for in vivo tumor diagnosis. Specific binding of the endogenous tissue inhibitor of metalloproteinase-2 (TIMP-2) to MT1-MMP has been previously described. In this study, biodistribution and imaging experiments were performed on MT1-MMP-overexpressing (S.1.5) and control (C.IV.3) tumor-inoculated mice using [(123)I]-recombinant human TIMP-2 (rhTIMP-2) as radioligand and [(123)I]-rhTIMP-1 as control. The expression profile was controlled in vitro and on tumor extracts. rhTIMP-2 as well as rhTIMP-1 were labeled using the Iodogen method and characterized. Biodistribution of [(123)I]-rhTIMP-2 showed a tumor uptake of 2.87% +/- 1.58% ID/g at 3 hours postinjection in S.1.5. Tumor values of [(123)I]-rhTIMP-1 and [(123)I]-rhTIMP-2 evaluated in S.1.5 and C.IV.3, respectively, were significantly lower. Planar imaging revealed significant uptake of [(123)I]-rhTIMP-2 in S.1.5 compared with contralateral background areas. This could not be observed in C.IV.3 and with [(123)I]-rhTIMP-1 in S.1.5. All tumors were well established (200-800 mg). These results suggest that rhTIMP-2 holds potential for development of radiotracers for in vivo imaging in overexpressing MT1-MMP but not in similar tumors that do not express this protease.
Disciplines :
Biochemistry, biophysics & molecular biology
Author, co-author :
Van Steenkiste, Magali
Oltenfreiter, Ruth
Frankenne, Francis
Vervoort, Liesbet
Maquoi, Erik ; Université de Liège - ULiège > Département des sciences cliniques > Labo de biologie des tumeurs et du développement
Noël, Agnès ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Biologie cellulaire et moléculaire appliquée à l'homme
Foidart, Jean-Michel ; Université de Liège - ULiège > Département des sciences cliniques > Gynécologie - Obstétrique - Labo de biologie des tumeurs et du développement
Van De Wiele, Christophe
De Vos, Filip
Language :
English
Title :
Membrane type 1 matrix metalloproteinase detection in tumors, using the iodinated endogenous [123I]-tissue inhibitor 2 of metalloproteinases as imaging agent.
Publication date :
2010
Journal title :
Cancer Biotherapy and Radiopharmaceuticals
ISSN :
1084-9785
eISSN :
1557-8852
Publisher :
Mary Ann Liebert, Inc., New Rochelle, United States - New York
Werb Z. ECM and cell surface proteolysis: Regulating cellular ecology. Cell 1997;91:439.
Brew K, Dinakarpandian D, Nagase H. Tissue inhibitors of metalloproteinases: Evolution, structure and function. Biochim Biophys Acta 2000;1477:267.
Lambert E, Dassé E, Haye B, et al. TIMPs as multifacial proteins. Crit Rev Oncol Hematol 2004;49:187.
Noel A, Jost M, Maquoi E. Matrix metalloproteinases at cancer tumor-host interface. Semin Cell Dev Biol 2008;19:52.
McCawley LJ, Matrisian LM. Matrix metalloproteinases: Multifunctional contributors to tumor progression. Mol Med Today 2000;6:149.
Scherer RL, McIntyre O, Matrisian L. Imaging matrix metalloproteinases in cancer. Cancer Metastasis Rev 2008;27:679.
Giersing BK, Rae MT, CarballidoBrea M, et al. Synthesis and characterization of 111In-DTPA-N-TIMP-2: A radiopharmaceutical for imaging matrix metalloproteinase expression. Bioconjug Chem 2001;12:964.
Van de Wiele C, Oltenfreiter R. Imaging probes targeting matrix metalloproteinases. Cancer Biother Radiopharm 2006;21:409.
Murphy G, Willenbrock F. Tissue inhibitors of matrix metalloproteinases. Methods Enzymol 1995;248:496.
Hutton M, Willenbrock F, Brocklehurst K, et al. Kinetic analysis of the mechanism of interaction of full length TIMP-2 and gelatinase A: Evidence for the existence of a low-affinity intermediate. Biochemistry 1998;37:10094.
Kulasegaram R, Giersing B, Page CJ, et al. In vivo evaluation of 111In-DTPA-N-TIMP-2 in Kaposi sarcoma associated with HIV infection. Eur J Nucl Med 2001;28:765.
Ueda J, Kajita M, Suanaga N, et al. Sequence-specific silencing of MT1-MMP expression suppresses tumor cell migration and invasion: Importance of MT1-MMP as a therapeutic target for invasive tumors. Oncogene 2003;22:8716.
Seiki M, Itoh Y. MT1-MMP: An enzyme with multidimensional regulation. Trends Biochem Sci 2004;29:285.
Arroyo AG, Genis L, Gonzalo P, et al. Matrix metalloproteinases: New routes to the use of MT1-MMP as a therapeutic target in angiogenesis-related disease. Curr Pharm Des 2007;13:1787.
De Clerck YA, Yean TD, Chan D, et al. Inhibition of tumor invasion of smooth muscle cell layers by recombinant human metalloproteinase inhibitor. Cancer Res 1991;51:2151.
Maquoi E, Frankenne F, Baramova E, et al. Membrane type 1 matrix metalloproteinase-associated degradation of tissue inhibitor of metalloproteinase 2 in human tumor cell lines. J Biol Chem 2000;75:11368.
Sounni NE, Baramova E, Munaut C, et al. Expression of membrane type I matrix metalloproteinase (MT1-MMP) in A2058 cells is associated with MMP-2 activation and increased tumor growth and vascularisation. Int J Cancer 2002;98:23.
Abramoff MD, Magelhaes PJ, Ram SJ. Image processing with ImageJ. Biophotonics Int 2004;11:36.
Haisma HJ, Hilgers J, Zurwaski VR Jr. Iodination of monoclonal antibodies for diagnosis and radiotherapy using a convenient one-vial method. J Nucl Med 1986;27:1890.
Maquoi E, Frankenne F, Noel A, et al. Type IV collagen induces matrix metalloproteinase 2 activation in HT1080 fibrosarcoma cells. Exp Cell Res 2000;261:348.
Lee MH, Rapti M, Murphy G. Unveiling the surface epitopes that render tissue inhibitor metalloproteinase-1 inactive against membrane type 1-matrix metalloproteinase. J Biol Chem 2003;278:40224.
Zucker S, Drews M, Conner C, et al. Tissue inhibitor of metalloproteinase-2 (TIMP-2) binds to the catalytic domain of the cell surface receptor, membrane type 1 matrix metalloproteinase 1 (MT1-MMP). J Biol Chem 1998;273:1216.
Strongin AY, Collier I, Bannikov G, et al. Mechanism of cell surface activation of 72-kDa type IV collagenase. J Biol Chem 1995;270:5331.
Emmert-Buck MR, Emonard HP, Corcoran ML, et al. Cell surface binding of TIMP-2 and pro-MMP-2/TIMP-2 complex. FEBS Lett 1995;364:28.
Butler GS, Butler MJ, Atkinson SJ, et al. The TIMP-2 membrane type 1 metalloproteinase "receptor" regulates the concentration and efficient activation of progelatinae A. A kinetic study. J Biol Chem 1998;273:871.
Bernardo MM, Fridman R. TIMP-2 (tissue inhibitor of metalloproteinase-2) regulates MMP-2 (matrix metalloproteinase-2) activity in the extracellular environment after pro-MMP-2 activation by MT1 (membrane type 1)-MMP. Biochem J 2003;374:739.
Uekita T, Itoh Y, Yana I, et al. Cytoplasmatic tail-dependent internalization of membrane type-1 matrix metalloproteinase is important for its invasion-promoting activity. J Cell Biol 2001;155:1345.
Jiang A, Lehti K, Wang X, et al. Regulation of membranetype matrix metalloproteinase 1 activity by dynaminmediated endocytosis. Proc Natl Acad Sci U S A 2001;98:13693.
Galvez BG, Salomon MR, Maria YM, et al. Caveolae are a novel pathway for membrane-type 1 matrix metalloproteinase traffic in human endothelial cells. Mol Biol Cell 2004;15:678.
Oltenfreiter R, Burvenich I, Staelens L, et al. Synthesis, quality control and in vivo evaluation of [I-123]rhTIMP-2, a potential tumor-imaging agent. J Labelled Comp Radiopharm 2005;48:387.
Osenkowski P, Toth M, Fridman M. Processing, shedding, and endocytosis of membrane type 1-matrix metalloproteinase (MT1-MMP). J Cell Physiol 2004;200:2.
Baker AH, Edwards DR, Murphy G. Metalloproteinase inhibitors: Biological actions and therapeutic opportunities. J Cell Sci 2002;115:3719.
